Reversal of direct oral anticoagulants: guidance from the anticoagulation forum
A Cuker, A Burnett, D Triller, M Crowther… - American journal of …, 2019 - Wiley Online Library
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
A Cuker, A Burnett, D Triller… - American journal …, 2019 - pubmed.ncbi.nlm.nih.gov
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
[PDF][PDF] Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
A Cuker, A Burnett, D Triller, M Crowther, J Ansell… - iacld.com
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
[PDF][PDF] Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
A Cuker, A Burnett, D Triller, M Crowther, J Ansell… - iacld.com
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
[PDF][PDF] Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
A Cuker, A Burnett, D Triller, M Crowther, J Ansell… - en.iacld.com
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
Reversal of Direct Oral Anticoagulants: Guidance from the Anticoagulation Forum
A Cuker, A Burnett, D Triller… - American …, 2019 - scholarlycommons.henryford.com
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
A Cuker, A Burnett, D Triller, M Crowther, J Ansell… - 2019 - researchsquare.com
Direct oral anticoagulants, or DOACs, are prescribed to millions of patients to prevent life-
threatening events such as stroke and thromboembolism. However, scenarios such as …
threatening events such as stroke and thromboembolism. However, scenarios such as …
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.
A Cuker, A Burnett, D Triller, M Crowther… - American Journal of …, 2019 - europepmc.org
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …